Clovis Oncology, Inc. (NASDAQ:CLVS) Files An 8-K Results of Operations and Financial Condition

Clovis Oncology, Inc. (NASDAQ:CLVS) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

(d) Exhibits.

Number and Description

99.1 Press Release, dated May 7, 2019.

Clovis Oncology, Inc. Exhibit
EX-99.1 2 a51980538ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Clovis Oncology Announces First Quarter 2019 Operating Results $33.1M in Rubraca® (rucaparib) global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC provided to FDA; RECIST response rate highly consistent with that shown at ESMO 2018 Targeting late 2019 for supplemental NDA filing for BRCA-mutant advanced prostate cancer; data update expected at Fall 2019 medical meeting Clovis-sponsored combination studies of lucitanib with rucaparib and Bristol-Myers Squibb’s Opdivo expected to begin in mid-2019; Entered into non-dilutive clinical trial financing up to $175M to fund quarterly expenses related to the ATHENA clinical trial beginning Q2 2019 Financing extends Clovis’ projected cash runway into 2022 $406.8M in cash,…
To view the full exhibit click here

About Clovis Oncology, Inc. (NASDAQ:CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

An ad to help with our costs